Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

As leukemia options grow, drugs jockey to be first-line therapies.

Dolgin E.

Nat Med. 2013 Jan;19(1):7. doi: 10.1038/nm0113-7. No abstract available.

PMID:
23295994
2.

Circumventing resistance to kinase-inhibitor therapy.

Druker BJ.

N Engl J Med. 2006 Jun 15;354(24):2594-6. No abstract available.

PMID:
16775240
3.

[Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].

Camañas-Troyano C, Calderón-Acedos C, Moriel-Sánchez Mdel C, Segura-Bedmar M.

Farm Hosp. 2013 Sep-Oct;37(5):428-9. doi: 10.7399/FH.2013.37.5.759. Spanish. No abstract available.

4.

Cancer-drug discovery and cardiovascular surveillance.

Groarke JD, Cheng S, Moslehi J.

N Engl J Med. 2013 Nov 7;369(19):1779-81. doi: 10.1056/NEJMp1313140. Epub 2013 Nov 1. No abstract available.

PMID:
24180496
5.

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.

Wongboonma W, Thongnoppakhun W, Auewarakul CU.

Exp Mol Pathol. 2012 Apr;92(2):259-65. doi: 10.1016/j.yexmp.2012.01.007. Epub 2012 Jan 31.

PMID:
22314255
6.

10 years of progress in chronic myelogenous leukemia.

Jabbour E, Mathisen MS, O'Brien S.

J Natl Compr Canc Netw. 2012 Sep;10(9):1049-53. No abstract available.

PMID:
22956803
8.

Dasatinib in chronic myelogenous leukemia.

Chu SC, Tang JL, Li CC.

N Engl J Med. 2006 Sep 7;355(10):1062-3; author reply 1063-4. No abstract available.

PMID:
16960978
9.

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.

J Clin Oncol. 2010 Apr 10;28(11):e169-71; author reply e172. doi: 10.1200/JCO.2009.26.4945. Epub 2010 Mar 1. No abstract available.

10.
11.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.

Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G.

Leuk Res. 2011 Jul;35(7):e118-20. doi: 10.1016/j.leukres.2011.03.021. Epub 2011 Apr 12. No abstract available.

PMID:
21489624
12.

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Narayanan V, Pollyea DA, Gutman JA, Jimeno A.

Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147. Review.

PMID:
23616953
13.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, Gambacorti-Passerini C, Boschelli F.

J Clin Oncol. 2009 Jan 20;27(3):469-71. doi: 10.1200/JCO.2008.19.8853. Epub 2008 Dec 15. No abstract available.

14.

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.

Haematologica. 2007 Mar;92(3):401-4.

15.

Loss of response to imatinib: mechanisms and management.

Shah NP.

Hematology Am Soc Hematol Educ Program. 2005:183-7.

PMID:
16304378
16.

First-line therapy for CML: nilotinib comes of age.

Davies J.

Lancet Oncol. 2011 Sep;12(9):826-7. doi: 10.1016/S1470-2045(11)70228-5. Epub 2011 Aug 17. No abstract available.

PMID:
21856227
17.

Ponatinib for chronic myeloid leukemia.

Goldman JM.

N Engl J Med. 2012 Nov 29;367(22):2148-9. doi: 10.1056/NEJMe1210796. No abstract available.

PMID:
23190226
18.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

19.

BCR-ABL1 compound mutations drive ponatinib resistance.

[No authors listed]

Cancer Discov. 2014 Nov;4(11):OF13. doi: 10.1158/2159-8290.CD-RW2014-186. Epub 2014 Sep 4.

20.

New concepts for CML clonality.

Khorashad JS, Deininger MW, O'Hare T.

Oncotarget. 2013 Jan;4(1):7-8. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk